To date, several studies have demonstrated the insulin-sensitizing effect of inositols, specifically in their physiological 40:1 ratio, in various endocrine and metabolic disorders; however, to date, only one trial has evaluated the use of inositols in T2DM [13]. The gene discussed is INS; the disease is metabolic disease.